ZMC(SH:600216) Xin Lang Cai Jing·2025-10-28 02:18Core Insights - Zhejiang Pharmaceutical (600216.SH) reported a total operating revenue of 6.695 billion yuan for Q3 2025, a decrease of 418 million yuan compared to the same period last year, representing a year-on-year decline of 5.87% [1] - The net profit attributable to shareholders was 933 million yuan, with net cash inflow from operating activities amounting to 1.489 billion yuan [1] Financial Performance - The latest debt-to-asset ratio is 20.69%, an increase of 0.89 percentage points from the previous quarter [3] - The latest gross profit margin is 37.49%, down by 2.32 percentage points from the previous quarter and down by 2.56 percentage points year-on-year [3] - The latest return on equity (ROE) stands at 8.44% [3] - The diluted earnings per share (EPS) is 0.97 yuan [3] Efficiency Metrics - The total asset turnover ratio is 0.48 times, a decrease of 0.06 times compared to the same period last year, reflecting an 11.68% year-on-year decline [3] - The inventory turnover ratio is 2.03 times, down by 0.12 times from the previous year, indicating a 5.59% year-on-year decrease [3] Shareholder Structure - The number of shareholders is 63,000, with the top ten shareholders holding a total of 468 million shares, accounting for 48.67% of the total share capital [3] - The largest shareholder is Xinchang Changxin Investment Development Co., Ltd., holding 21.6 million shares [3]